RPM Reimbursement Requires FDA-Cleared Devices, and Cellular Wins on Adherence

CMS requires remote patient monitoring programmes to use FDA-cleared medical devices in order to qualify for reimbursement. Cellular connectivity is not mandated, but it is frequently preferred because cellular devices transmit automatically, which improves patient adherence and removes technical barriers.

The connectivity preference is a design conclusion drawn from behaviour rather than from engineering. A Bluetooth device that pairs to a phone is cheaper and technically capable, and it fails in an entirely predictable way: it depends on the patient having a compatible phone, keeping an app installed, keeping Bluetooth on, and re-pairing after an update. Each of those is a small probability of failure, and across a monitoring period they compound into missed days — which under the billing rules are not just clinical gaps but unbilled ones.

A cellular device removes the patient from the data path entirely. Take a reading and the reading is transmitted; there is nothing to open, pair or troubleshoot. It costs more per unit and carries a subscription, and for a population that is older or less comfortable with technology it is routinely the cheaper option once missed transmissions are priced in. This is a case where the reimbursement rules and good device design point the same direction, which is not always true.